

FDA clears Adherium's usage tracker for AstraZeneca inhaler

04 September 2017 | News

The FDA clearance is Adherium's third. Its SmartInhaler offerings include devices and apps that help patients manage respiratory disease



Australian smart inhaler maker Adherium has scored an FDA nod for its SmartTouch device, for use with AstraZeneca's Symbicort aerosol inhalers.

This device is designed to improve medication adherence and attaches to a patient's inhaler and tracks the date and time that it is used. It then transmits this data to an app on a smartphone or tablet. Physicians can look at a patient's usage trends to tailor his or her treatment plan.

Arik Anderson, CEO, Adherium said, "The SmartTouch for Symbicort is the most advanced SmartInhaler product to date for Adherium and a key product in our strategic collaboration with AstraZeneca by bringing the benefits of digital monitoring to patients and their physicians."

The FDA clearance is Adherium's third. Its SmartInhaler offerings include devices and apps that help patients manage respiratory disease.

Adherium in a statement said, "The device can be used in home monitoring programs—such as those geared at preventing hospital readmission—where drug adherence after hospital discharge is an important goal."